Predictors of mortality in tocilizumab treated severe covid-19
K. Pagkratis (Corfu, Greece), S. Chrysikos (Corfu, Greece), E. Antonakis (Corfu, Greece), A. Pandi (Corfu, Greece), C. Kosti (Corfu, Greece), E. Markatis (Corfu, Greece), G. Hillas (Corfu, Greece), A. Digalaki (Corfu, Greece), S. Koukidou (Corfu, Greece), E. Chaini (Corfu, Greece), A. Afthinos (Corfu, Greece), K. Dimakou (Corfu, Greece), I. Papanikolaou (Corfu, Greece)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2613
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Pagkratis (Corfu, Greece), S. Chrysikos (Corfu, Greece), E. Antonakis (Corfu, Greece), A. Pandi (Corfu, Greece), C. Kosti (Corfu, Greece), E. Markatis (Corfu, Greece), G. Hillas (Corfu, Greece), A. Digalaki (Corfu, Greece), S. Koukidou (Corfu, Greece), E. Chaini (Corfu, Greece), A. Afthinos (Corfu, Greece), K. Dimakou (Corfu, Greece), I. Papanikolaou (Corfu, Greece). Predictors of mortality in tocilizumab treated severe covid-19. 2613
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|